keyword
MENU ▼
Read by QxMD icon Read
search

DMARDs

keyword
https://www.readbyqxmd.com/read/28815115/discovering-adverse-drug-events-combining-spontaneous-reports-with-electronic-medical-records-a-case-study-of-conventional-dmards-and-biologics-for-rheumatoid-arthritis
#1
Liwei Wang, Majid Rastegar-Mojarad, Sijia Liu, Huaji Zhang, Hongfang Liu
The use of multiple data sources has been preferred in the surveillance of adverse drug events due to shortcomings of using only a single source. In this study, we proposed a framework where the ADEs associated with interested drugs are systematically discovered from the FDA's Adverse Event Reporting System (AERS), and then validated through mining unstructured clinical notes from Electronic Medical Records (EMRs). This framework has two features. First, a higher priority was given to clinical practice during signal detection and validation...
2017: AMIA Summits on Translational Science Proceedings
https://www.readbyqxmd.com/read/28814431/calprotectin-as-a-marker-of-inflammation-in-patients-with-early-rheumatoid-arthritis
#2
Maria Karolina Jonsson, Nina Paulshus Sundlisæter, Hilde Haugedal Nordal, Hilde Berner Hammer, Anna-Birgitte Aga, Inge Christoffer Olsen, Karl Albert Brokstad, Désirée van der Heijde, Tore K Kvien, Bjørg-Tilde Svanes Fevang, Siri Lillegraven, Espen A Haavardsholm
OBJECTIVES: Calprotectin is an inflammatory marker of interest in rheumatoid arthritis (RA). We evaluated whether the level of calprotectin was associated with disease activity, and if it was predictive of treatment response and radiographic progression in patients with early RA. METHODS: Plasma from disease-modifying antirheumatic drug (DMARD)-naïve patients with RA fulfilling 2010 American College of Rheumatology/European League Against Rheumatism classification criteria with symptom duration <2 years was analysed for calprotectin at baseline, and after 1, 3 and 12 months...
August 16, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28812149/-uveitis-in-spondyloarthritis
#3
REVIEW
M Rudwaleit, K Walscheid, A Heiligenhaus
Acute anterior uveitis (AAU) is the most frequent uveitis subtype. It is often associated with HLA-B27 and with inflammatory rheumatic diseases, in particular with spondyloarthritis (SpA), which itself is strongly associated with HLA-B27. About 40-60% of patients with AAU have an associated spondyloarthritis, and 20-40% of patients with spondyloarthritis also have uveitis. The incidence of AAU in patients with SpA clearly correlates with disease duration. The AAU has an acute onset, usually affects only one eye at a time, and shows a tendency for recurrence...
August 15, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28812127/-uveitis-in-juvenile-idiopathic-arthritis
#4
I Foeldvari, K Walscheid, A Heiligenhaus
BACKGROUND: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA). It occurs, according to German registry data, in around 12% of JIA patients and can lead to a loss of vision, especially in cases of delayed diagnosis and/or inadequate therapy. OBJECTIVE: A review of current aspects of diagnosis and therapy was carried out. MATERIAL AND METHODS: This is a review article of the current literature. RESULTS: The risk of uveitis is significantly elevated in patients with an oligoarticular course of JIA, ANA positivity and young age at onset of JIA...
August 15, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/28804988/patterns-of-systemic-treatment-for-psoriatic-arthritis-in-the-united-states-2004-2015
#5
Moa P Lee, Joyce Lii, Yinzhu Jin, Rishi J Desai, Daniel H Solomon, Joseph F Merola, Seoyoung C Kim
OBJECTIVE: To examine trends in use of systemic disease-modifying antirheumatic drugs (DMARD) among patients with psoriatic arthritis (PsA) in the U.S. METHODS: Using claims data (2004-2015) from a large U.S. commercial healthplan, we identified patients with PsA who initiated DMARDs. We examined baseline patient characteristics and initial treatment patterns. We then assessed changes in the DMARD regimen over the 12-month period after the 1(st) DMARD initiation date...
August 13, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/28794513/rheumatoid-arthritis-dmard-de-escalation-let-the-patient-guide-you
#6
Yoshiya Tanaka
No abstract text is available yet for this article.
August 10, 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/28794381/clinical-characteristics-of-rheumatoid-arthritis-patients-achieving-functional-remission-after-six-months-of-non-tumor-necrosis-factor-biological-disease-modifying-antirheumatic-drugs-dmards-treatment
#7
Yusuke Miwa, Mayu Saito, Hidekazu Furuya, Ryo Yanai, Yuzo Ikari, Tomoki Hayashi, Tsuyoshi Kasama, Yoichi Toyoshima, Katsunori Inagaki
Objectives We aimed to identify the factors that predict the likelihood of remission based on a health assessment questionnaire (HAQ) in rheumatoid arthritis (RA) patients who received non-tumor necrosis factor (TNF) biologics for six months before they commenced definitive treatment. Methods The subjects consisted of 97 RA patients treated with tocilizumab or abatacept for 6 months. The following characteristics were investigated: age, gender, body mass index, steroid and methotrexate dosage, serum matrix metalloproteinase-3 levels, simplified disease activity index (SDAI) score, HAQ score (for assessing the activities of daily living [ADL]) and the short form (SF)-36 score (for assessing the quality of life [QOL])...
August 10, 2017: Internal Medicine
https://www.readbyqxmd.com/read/28790811/retrospective-analysis-to-describe-associations-between-tumor-necrosis-factor-alpha-inhibitors-and-copd-related-hospitalizations
#8
Neil A Accortt, James B Chung, Machaon Bonafede, Brendan L Limone, David M Mannino
BACKGROUND: Limited information exists on the impact of tumor necrosis factor inhibition on COPD exacerbations. This retrospective study characterized this impact among COPD patients with underlying autoimmune conditions, exposed to tumor necrosis factor inhibitors (TNFi) and/or non-biologic disease-modifying antirheumatic drugs (DMARDs). PATIENTS AND METHODS: Adult COPD patients with ≥1 diagnosis for rheumatoid arthritis (RA), psoriasis (PsO), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) before or within 6 months following the index COPD diagnosis were identified from the Truven Health MarketScan(®) databases...
2017: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/28790807/non-persistence-and-non-adherence-to-mtx-therapy-in-patients-with-rheumatoid-arthritis-a-retrospective-cohort-study-based-on-german-ra-patients
#9
Sabrina Müller, Thomas Wilke, Andreas Fuchs, Ulf Maywald, Jan-Paul Flacke, Harald Heinisch, Klaus Krüger
OBJECTIVE: This study aimed to assess the level of nonpersistence (NP) and nonadherence (NA) to methotrexate (MTX) therapy in German patients with rheumatoid arthritis (RA). MATERIALS AND METHODS: Based on German claims data, RA patients who received a MTX therapy (subgroup: treatment-naive patients) were analyzed. NP was defined as treatment gap >12 weeks. Regarding NA, it is the overall medication possession ratio (MPR) during an observational period of 12 or 24 months after therapy, and the MPR is calculated only for the periods of therapy continuation; NA was defined as MPR <80%...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/28764705/drug-survival-of-second-biological-dmard-therapy-in-patients-with-rheumatoid-arthritis-a-retrospective-non-interventional-cohort-analysis
#10
Thomas Wilke, Sabrina Mueller, Sze Chim Lee, Istvan Majer, Marieke Heisen
BACKGROUND: Since persistence to first biological disease modifying anti-rheumatic drugs (bDMARDs) is far from ideal in rheumatoid arthritis (RA) patients, many do receive a second and/or third bDMARD treatment. However, little is known about treatment persistence of the second-line bDMARD and it is specifically unknown whether the mode of action of such a treatment is associated with different persistence rates. We aimed to assess discontinuation-, re-initiation- or continuation-rates of a 2nd bDMARD therapy as well as switching-rates to a third biological DMARD (3rd bDMARD) therapy in RA patients...
August 2, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/28764693/the-relationship-between-demographic-and-disease-related-variables-and-health-related-quality-of-life-in-patients-with-axial-spondyloarthritis
#11
Gudrun Rohde, Kari Hansen Berg, Anne Prøven, Glenn Haugeberg
BACKGROUND: Axial spondyloarthritis (ax-SpA) is a chronic inflammatory disease of the spine causing pain, stiffness, loss in physical function, and fatigue. Therefore, the physical and psychological burden of having this chronic disease can reduce the quality of life. We aimed to explore the relationship between demographic- and disease-related variables and health-related quality of life (HRQoL) in patients with ax-SpA. METHODS: Demographic- and disease-related, HRQoL-related and treatment data were collected...
August 1, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/28750567/impact-of-pharmacogenomics-upon-the-therapeutic-response-to-etanercept-in-psoriasis-and-psoriatic-arthritis
#12
Giuseppe Murdaca, Simone Negrini, Ottavia Magnani, Elena Penza, Marco Pellecchio, Francesco Puppo
TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of chronic inflammatory immune-mediated diseases. Etanercept is a decoy receptor" for TNF-α and it is composed of two p75 TNF-α receptors fused to human IgG1. Areas covered: We discuss the potential role of pharmacogenetics in predicting the response to etanercept in patients with Ps and PsA. Expert opinion: Pharmacogenetics represents the new frontier for the discovery of potential genetic markers of biological response to TNF-α inhibitors...
July 28, 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/28740368/impact-of-adherence-to-biological-agents-on-health-care-resource-utilization-for-patients-over-the-age-of-65-years-with-rheumatoid-arthritis
#13
Urja Lathia, Emmanuel M Ewara, Francois Nantel
OBJECTIVE: Poor adherence to therapy increases the patient and societal burden and complexity of chronic diseases such as rheumatoid arthritis (RA). In the past 15 years, biologic disease-modifying anti-rheumatic drugs (DMARDs) have revolutionized the treatment of RA. However, little data are available on the impact of adherence to biologics on health care resources. The objective of the study was to determine the long-term health care resource utilization patterns of RA patients who were adherent to biologic DMARD therapy compared to RA patients who were non-adherent to biologic DMARD therapy in an Ontario population and to determine factors influencing adherence...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/28739353/incidence-of-tuberculosis-among-patients-with-rheumatoid-arthritis-using-tnf-blockers-in-brazil-data-from-the-brazilian-registry-of-biological-therapies-in-rheumatic-diseases-registro-brasileiro-de-monitora%C3%A3-%C3%A3-o-de-terapias-biol%C3%A3-gicas-biobadabrasil
#14
Claudia Leiko Yonekura, Rene Donizeti Ribeiro Oliveira, David C Titton, Roberto Ranza, Aline Ranzolin, André L Hayata, Ângela Duarte, Inês G Silveira, Hellen M da S de Carvalho, Júlio C Bertacini de Moraes, Mirhelen Mendes de Abreu, Valéria Valim, Washington Bianchi, Claiton Viegas Brenol, Ivanio A Pereira, Izaias Costa, José C Macieira, José R S Miranda, Luiz S Guedes-Barbosa, Manoel B Bertolo, Maria Fátima Lobato da C Sauma, Marília B G Silva, Marlene Freire, Morton A Scheinberg, Roberto A Toledo, Sheila K F Oliveira, Vander Fernandes, Marcelo M Pinheiro, Glaucio Castro, Walber Pinto Vieira, Cesar Emile Baaklini, Antonio Ruffino-Netto, Geraldo da Rocha Castelar Pinheiro, Ieda Maria Magalhães Laurindo, Paulo Louzada-Junior
OBJECTIVES: To assess the incidence of tuberculosis and to screen for latent tuberculosis infection among Brazilians with rheumatoid arthritis using biologics in clinical practice. PATIENTS AND METHODS: This cohort study used data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitoração de Terapias Biológicas - BiobadaBrasil), from 01/2009 to 05/2013, encompassing 1552 treatments, including 415 with only synthetic disease-modifying anti-rheumatic drugs, 942 synthetic DMARDs combined with anti-tumor necrosis factor (etanercept, infliximab, adalimumab) and 195 synthetic DMARDs combined with other biologics (abatacept, rituximab and tocilizumab)...
July 21, 2017: Revista Brasileira de Reumatologia
https://www.readbyqxmd.com/read/28737992/temporal-trends-in-use-of-biologic-dmards-for-rheumatoid-arthritis-in-the-united-states-a-cohort-study-of-publicly-and-privately-insured-patients
#15
Rishi J Desai, Daniel H Solomon, Yinzhu Jin, Jun Liu, Seoyoung C Kim
BACKGROUND: Ten biologic disease-modifying antirheumatic drugs (bDMARDs) are available as treatment for rheumatoid arthritis (RA), but relatively little is known about population-level time trends in the use of these agents. OBJECTIVE: To describe time trends in the use of bDMARDs in RA patients with private or public insurance in the United States. METHODS: Claims data from private (Optum Clinformatics, 2004-2015) and public (Medicaid Analytic eXtract [MAX], 2000-2010) insurance programs were used...
August 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28737988/patterns-of-care-for-biologic-dosing-outliers-and-nonoutliers-in-biologic-naive-patients-with-rheumatoid-arthritis
#16
Thomas Delate, Roxanne Meyer, Daniel Jenkins
BACKGROUND: Although most biologic medications for patients with rheumatoid arthritis (RA) have recommended fixed dosing, actual biologic dosing may vary among real-world patients, since some patients can receive higher (high-dose outliers) or lower (low-dose outliers) doses than what is recommended in medication package inserts. OBJECTIVE: To describe the patterns of care for biologic-dosing outliers and nonoutliers in biologic-naive patients with RA. METHODS: This was a retrospective, longitudinal cohort study of patients with RA who were not pregnant and were aged ≥ 18 and < 90 years from an integrated health care delivery system...
August 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28737053/efficacy-of-baricitinib-in-the-treatment-of-rheumatoid-arthritis
#17
Christophe Richez, Marie-Elise Truchetet, Marie Kostine, Thierry Schaeverbeke, Bernard Bannwarth
although the outcome for patients with rheumatoid arthritis (ra) has improved in the past decades, adequate disease control cannot be achieved in a substantial proportion of patients. new drugs with a novel mechanism of action, may represent a valuable addition to the current armamentarium. Areas covered: This review focuses on the pharmacodynamics and pharmacokinetics of baricitinib. Furthermore, the article summarizes and comments the drug's efficacy and safety profile in RA patients. Expert opinion: Baricitinib is an oral targeted synthetic (ts) disease-modifying antirheumatic drug (DMARD) that mainly inhibits JAK1 and JAK2...
July 27, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28736274/biomarkers-as-a-treatment-guide-in-rheumatoid-arthritis
#18
Tsutomu Takeuchi
It is anticipated that biomarkers support rheumatologists to judge a group of patients that can improve the diagnosis and prognosis, and further facilitate appropriate and precise treatment with targeted therapy. In particular, biomarkers for predicting and monitoring response to biological disease modifying anti-rheumatic drugs (DMARDs) are demanding. Given the mechanism action of biological DMARDs is much more simple than the conventional synthetic DMARDs, a variety of approaches to find such biomarkers has been taken recent years...
July 20, 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/28733473/do-depression-and-anxiety-reduce-the-likelihood-of-remission-in-rheumatoid-arthritis-and-psoriatic-arthritis-data-from-the-prospective-multicentre-nor-dmard-study
#19
Brigitte Michelsen, Eirik Klami Kristianslund, Joseph Sexton, Hilde Berner Hammer, Karen Minde Fagerli, Elisabeth Lie, Ada Wierød, Synøve Kalstad, Erik Rødevand, Frode Krøll, Glenn Haugeberg, Tore K Kvien
OBJECTIVE: To investigate the predictive value of baseline depression/anxiety on the likelihood of achieving joint remission in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) as well as the associations between baseline depression/anxiety and the components of the remission criteria at follow-up. METHODS: We included 1326 patients with RA and 728 patients with PsA from the prospective observational NOR-DMARD study starting first-time tumour necrosis factor inhibitors or methotrexate...
July 21, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/28732151/patients-attitudes-and-experiences-of-disease-modifying-anti-rheumatic-drugs-in-rheumatoid-arthritis-and-spondyloarthritis-a-qualitative-synthesis
#20
Ayano Kelly, Kathleen Tymms, David J Tunnicliffe, Daniel Sumpton, Chandima Perera, Kieran Fallon, Jonathan C Craig, Walter Abhayaratna, Allison Tong
OBJECTIVES: Non-adherence to disease-modifying anti-rheumatic drugs (DMARDS) in rheumatoid arthritis (RA) and spondyloarthritis (SpA) results in increased disease activity and symptoms and poorer quality of life. We aimed to describe patients' attitudes and experiences of DMARDs in RA and SpA to inform strategies to improve medication adherence. METHODS: Databases (MEDLINE, Embase, PsycINFO, CINAHL) were searched to January 2016. Thematic synthesis was used to analyze the findings...
July 21, 2017: Arthritis Care & Research
keyword
keyword
86203
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"